Mangoceuticals, Inc., a Texas-based pharmaceutical company, has announced a special meeting of stockholders to consider and vote on several key proposals. The meeting, scheduled for a yet-to-be-determined date in 2024, will address a proposed reverse stock split of the company's outstanding common stock, the adoption of the First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan, and the potential adjournment of the meeting if necessary to solicit additional proxies. The reverse stock split aims to maintain compliance with Nasdaq's minimum bid price requirement by reducing the number of shares outstanding, thereby increasing the per-share price. The amendment to the equity incentive plan seeks to increase the share reserve and the number of shares that may be issued under the plan, which is crucial for attracting and retaining key personnel. The board unanimously recommends voting in favor of all proposals.

Mangoceuticals, Inc., a Texas-based pharmaceutical company, has announced a special meeting of stockholders to consider and vote on several key proposals. The meeting, scheduled for a yet-to-be-determined date in 2024, will address a proposed reverse stock split of the company's outstanding common stock, the adoption of the First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan, and the potential adjournment of the meeting if necessary to solicit additional proxies. The reverse stock split aims to maintain compliance with Nasdaq's minimum bid price requirement by reducing the number of shares outstanding, thereby increasing the per-share price. The amendment to the equity incentive plan seeks to increase the share reserve and the number of shares that may be issued under the plan, which is crucial for attracting and retaining key personnel. The board unanimously recommends voting in favor of all proposals.